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Abstract Purpose: Deposition of
fibrin in the alveolar space is a hall-
mark of acute lung injury (ALI).
Plasminogen activator inhibitor-1
(PAI-1) is an antifibrinolytic agent
that is activated during inflammation.
Increased plasma and pulmonary
edema fluid levels of PAI-1 are
associated with increased mortality in
adults with ALI. This relationship has
not been examined in children. The
objective of this study was to test
whether increased plasma PAI-1 lev-
els are associated with worse clinical
outcomes in pediatric patients with
ALI. Design/methods: We mea-
sured plasma PAI-1 levels on the first
day of ALI among 94 pediatric
patients enrolled in two separate
prospective, multicenter investiga-
tions and followed them for clinical
outcomes. All patients met American
European Consensus Conference cri-
teria for ALI. Results: A total of 94
patients were included. The median
age was 3.2 years (range 16 days–
18 years), the PaO2/FiO2 was
141 ± 72 (mean ± SD), and overall
mortality was 14/94 (15%). PAI-1
levels were significantly higher in
nonsurvivors compared to survivors
(P \ 0.01). The adjusted odds of
mortality doubled for every log
increase in the level of plasma PAI-1
after adjustment for age and severity
of illness. Conclusions: Higher
PAI-1 levels are associated with
increased mortality and fewer venti-
lator-free days among pediatric
patients with ALI. These findings
suggest that impaired fibrinolysis may
play a role in the pathogenesis of ALI
in pediatric patients and suggest that
PAI-1 may serve as a useful bio-
marker of prognosis in patients with
ALI.
Keywords Accurate respiratory
distress syndrome  Acute lung
injury  Clinical studies  Pediatrics 
Plasminogen activator inhibitor-1
(PAI-1)
Introduction
Acute lung injury (ALI) is a life-threatening disorder
characterized by severe inflammation in the lungs and
frequently by the occurrence of multiple organ failure [1].
ALI is a major cause of morbidity and mortality among
critically ill children and accounts for approximately 1–4%
of all pediatric intensive care unit (PICU) admissions; up to
8% of all mechanically ventilated children meet criteria for
ALI. There are both similarities and significant differences
in the predisposing causes and clinical course of ALI in
adults and children [2–7]. The reported mortality from ALI
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in the pediatric age group overall ranges from 8 to 60% with
higher mortality reported among immunocompromised
children [2–8]. The only therapy that has been proven to
reduce mortality in ALI in adults is the use of lung-
protective ventilatory strategy [1]. Insight into pathophys-
iological derangements that characterize early clinical ALI
in children may help in identifying patients at greatest risk
and guide the development of new therapies for this
devastating disorder.
The pathophysiology of ALI is characterized by
disruption of the lung endothelial and alveolar epithelial
barriers, translocation of protein-rich edema fluid into
the alveoli, release of pro-inflammatory cytokines, and
deposition of fibrin in the alveolar space [9]. The
deposition of fibrin in the alveoli is the net result of an
alteration in the balance of coagulation and fibrinolysis.
Early in the course of ALI, there is elevation of PAI-1
activity in plasma and air spaces, which is accompanied
by a decrease in alveolar fibrinolysis [10–14]. Excessive
fibrin deposition enhances inflammatory responses by
activating endothelial cells to produce pro-inflammatory
mediators and increases lung vascular permeability [15].
Therefore, assessing the extent of fibrinolysis in ALI
may be important from a pathogenetic and prognostic
standpoint [9].
Previous studies in adults with ALI have reported
that an early increase in plasma levels of PAI-1 is an
independent risk factor for mortality and adverse clin-
ical outcomes and therefore, measurement of PAI-1
may be useful to (a) identify those at highest risk of
adverse clinical outcomes, and (b) lead to the devel-
opment of new therapies [9, 13, 16]. There have been
no studies to date examining the relationship of plasma
PAI-1 levels to clinical outcomes in pediatric patients
with ALI. It is not clear whether the association of
elevated PAI-1 levels with increased mortality descri-
bed in adults is true for pediatric patients as well
because there are significant differences between adults
and children in terms of (1) predisposing conditions
leading to ALI, (2) mortality from ALI, and (3)
response to therapy with activated protein C in patients
with sepsis, which is a common predisposing cause of
ALI. Therefore, in order to test the relationship between
plasma levels of PAI-1 and mortality, we hypothesized
that early elevation of plasma PAI-1 would be associ-
ated with increased mortality and fewer ventilator-free
days in pediatric patients with ALI.
Methods
Human subjects
The study was carried out on pediatric patients with ALI
enrolled in two clinical trials of ALI.
1. Prospective observational trial of ALI in pediatric
patients with ALI. A total of 320 patients with ALI,
age 1 month to 18 years, were enrolled at Children’s
Hospital and Research Center, Oakland, CA, USA
(CHRCO) and University of California, San Francisco
(UCSF) Children’s Hospital, USA. The overall mor-
tality in the cohort was 22% [4]. Plasma samples were
obtained from 72 patients within 24 h of development
of ALI.
2. Randomized clinical trial of prone positioning in the
management of pediatric patients with ALI. A total of
102 patients with ALI, age 2 weeks to 18 years were
enrolled from seven U.S. PICUs including CHRCO
and UCSF Children’s Hospital. Patients were random-
ized to the supine or prone position. The primary
outcome was the number of ventilator-free days. There
was no difference in the number of ventilator-free days
in the two arms and overall. The overall mortality in
this trial was 8% [2]. Plasma samples were obtained
within 24 h of development of ALI from 22 patients in
this trial.
Both of these studies prospectively identified and
enrolled pediatric patients meeting the standard American
European Consensus Conference (AECC) criteria for ALI
[17]. The AECC criteria for definition of ALI are PaO2/
FiO2 \ 300, bilateral opacities on the chest radiograph,
and either a pulmonary wedge pressure of less than
18 mmHg or the absence of clinical evidence of left atrial
hypertension.
The research featured here is based on a subset of ALI
patients enrolled in the two studies. We could not include
all of the enrolled patients in the parent studies because
collection of blood samples was not originally a part of
either of the primary studies. This study was added on as
an ancillary study to test the pathogenetic and prognostic
value of biological markers in ALI. Blood samples could
be collected only in a subset of patients because (1) the
ancillary study with collection of blood samples from
enrolled patients started after the studies were under way,
(2) collection of blood samples was limited to centers that
participated in the ancillary study, and (3) collection of
blood samples was possible only for patients in whom
consent for blood collection could be obtained. We
included all 94 patients from the two studies who had a
plasma sample collected within 24 h of meeting criteria
for the diagnosis of ALI.
There was no difference in ventilator strategies
between the ALI patients who had blood samples col-
lected for the biomarker studies and those who did not.
Study guidelines based on current best practice were
followed for ventilator management and extubation in the
interventional trial of prone positioning. In the ALI
observational trial, ventilator management was as per the
physician’s preference, but a protocol was followed to
guide the timing of extubation. However, management
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decisions were made by clinicians blinded to PAI-1 levels
and therefore are unlikely to have led to any bias.
Data collection
Patient demographics, overall clinical status at onset of
ALI, pediatric risk of mortality (PRISM) III score, diag-
nosis associated with the onset of ALI, PaO2/FiO2, chest
radiograph findings, duration of mechanical ventilation,
and 28-day all cause in-hospital mortality were collected
at enrollment and during the hospital stay. Patients were
followed for 28 days or in-hospital death.
Measurements
Plasma PAI-1 levels were measured on samples drawn
within 24 h after meeting criteria for ALI. Plasma PAI-1
was measured using a standard ELISA technique with
plates and reagents supplied by American Diagnostics,
Greenwich, CT, USA. The protocol was performed
essentially as recommended by the manufacturers and as
published [18].
Outcomes
The primary outcome was mortality at 28 days and the
secondary outcome was ventilator-free days (VFD).
Data analysis
Normally distributed data are presented as mean and SD
and non-normally distributed data are presented as med-
ian and ranges. We compared non-normally distributed
continuous variables using the nonparametric Spearman’s
correlation test. We also compared VFD across ordered
categories of plasma PAI-1 levels using the test for trend
across ordered categories. We used regression models to
control for the potential confounding effect of age and
severity of illness on mortality and VFD. Due to their
right skewed distribution, and as has been done in pre-
vious studies, we log-transformed PAI-1 levels prior to
carrying out parametric tests to compare PAI-1 levels
within groups and for regression analysis. The statistical
analysis was carried out on Stata 9 software (Stata, Col-
lege Station, TX, USA).
Results
A total of 94 patients were available to us for this study.
The baseline characteristics and primary diagnoses pre-
disposing to ALI among these patients are shown in
Table1.
Since the present study includes only those patients
from whom blood samples were collected within the first
24 h of diagnosis of ALI, we compared the baseline
characteristics among patients having blood samples with
Table 1 Baseline characteristics of 94 patients with ALI included in the current study and of patients enrolled in the parent studies
(A) ALI observational study (B) Prone positioning study Current study
Overall
cohort (n = 320)
Included
here (n = 72)
P Overall
cohort (n = 101)
Included
here (n = 22)
P Included
here (A ? B)
(n = 94)
P
Age (years) 3.4 (0–18) 3.2 (0.5–18) 0.7 2.1 (0.3–11) 4.1 (0.04–17) 3.2 (0.04–18) 0.5
Male 57% 51% 0.4 52% 54% 0.8 49 (52%) 0.8
Race
Caucasian 38% 40% 0.5 55% 35% 0.08 35 (39%) 0.7
Hispanic 18% 23% 24% 20% 20 (22%)
African American 22% 21% 11% 35% 22 (24%)
Asian 8% 4% 4% 0% 3 (3%)
Other/unknown 15% 11% 6% 10% 10 (11%)
Primary diagnosis associated with ALI
Pneumonia 20% 33% 0.1 56% 45% 0.6 34 (36%) 0.2
Viral/bronchitis 17% 18% 14% 18% 17 (18%)
Aspiration 15% 14% 11% 18% 14 (15%)
Sepsis and meningitis 14% 14% 15% 18% 14 (15%)
Others 33% 21% 5% 0% 15 (16%)
Physiological variables
PaO2/FiO2 161 ± 74 145 ± 74 0.09 100 ± 65 125 ± 64 0.1 141 ± 72 0.2
PRISM III (unadjusted) 10 ± 9 10 ± 6 1 11 ± 8 11 ± 8 0.96 10 ± 7 0.6
Oxygenation index 10 ± 10 12 ± 12 0.07 16 ± 11 15 ± 10 0.31 13 ± 12 0.4
Data are expressed as median (range), mean ± SD, or n (%)
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patients in the entire cohort in each of the parent studies
(Table 1). For the 72 patients drawn from the ALI
observational study, the PaO2/FiO2 was 145 ± 74,
PRISM score was 10 ± 6, and the VFDs were 14 ± 10.
These data are not statistically different from the values
reported for the overall cohort in the parent study
(Table 1) [4]. Among the 22 patients drawn from the
prone positioning trial, the PaO2/FiO2 was 125 ± 64, the
PRISM score was 11 ± 9, and the VFDs were 15 ± 8.
These data are not statistically different from the values
reported for the overall cohort in the parent study (see
Table 1) [2, 4].
Primary outcome (mortality)
A total of 14/94 (15%) patients died prior to hospital
discharge. The primary diagnosis, associated multiorgan
failure and attributable causes of death are listed in
Table 2. PAI-1 levels were higher among nonsurvivors
than among survivors. Among nonsurvivors, the median
PAI-1 level was 350 ng/mL with an interquartile range
from 232 to 1,083 ng/mL, whereas among the survivors
the median PAI-1 level was 239 ng/mL with the inter-
quartile range from 90 to 393 ng/mL. Due to their non-
normal distribution, PAI-1 levels were log-transformed
before applying parametric tests to compare the levels
between survivors and nonsurvivors (Fig. 1). There was a
statistically significant difference between PAI-1 levels
among survivors and nonsurvivors (P \ 0.01). Using
multivariate logistic regression to adjust for age and the
severity of illness, the odds of mortality increased by 2.0
for every log increase in the level of plasma PAI-1
(Table 3). There was no statistically significant difference
in PAI-1 levels based on the primary diagnoses.
Secondary outcome (VFD)
Ventilator-free days were calculated as the number of
days of unassisted breathing between enrollment on day 0
until day 28 when the patient was alive [19]. Increasing
PAI-1 levels were correlated with the need for prolonged
mechanical ventilation. Spearman’s correlation was
q = -0.26 (P \ 0.02). The number of VFDs was lower
among patients with increasing quartiles of plasma PAI-1
levels (P \ 0.02) (Fig. 2). By multivariate linear regres-
sion that was adjusted for age and severity of illness, there
Fig. 1 Boxplots of log-transformed day 1 plasma levels of
plasminogen activator inhibitor-1 (PAI-1) stratified by 28-day
mortality among 94 pediatric patients with acute lung injury (ALI).
There was a statistically significant difference in the levels between
survivors and nonsurvivors (P \ 0.01)
Table 2 Diagnosis, multiorgan failure, and cause of death among nonsurvivors
Primary diagnosis Multi-organ failure Final cause of death
Leukemia ARDS, CV, heme, renal Brain death
Lupus flare ARDS, renal, hep, GI, heme, Brain death
Pneumonia (pneumococcal) ARDS, CV, heme, CNS Cardiac arrest with
clinical herniation
Vasoocclusive disease and graft-versus-host
disease after BMT
ARDS, hepatic, renal, heme, CV No escalation of care
Sepsis and candida superinfection ARDS, CV, heme, hep, renal No escalation of care
Sepsis (pneumococcal) ARDS, CV, renal, hepatic, heme, CNS Withdrawal of support
Pneumonia (influenza A and candida) ARDS, heme, renal, liver Withdrawal of support
Sepsis (strept viridans) ARDS, CV, heme, GI Withdrawal of support
Cardiac arrest, pulmonary HTN ARDS, CV, hepatic Withdrawal of nitric oxide
Adenoviral pneumonia ARDs, bleeding on ECLS Withdrawal of support
Aspiration pneumonia ARDS, heme Withdrawal of support
Meningococcemia with peripheral ischaemia ARDS, renal, CV, heme, hep, CNS Withdrawal of support
Head trauma ARDS, CV, heme No escalation of care
Sickle cell disease, stroke, desferoxmine toxicity ARDS, CV, heme, CNS Withdrawal of support
ARDS Acute respiratory distress syndrome, CV cardiovascular, heme hematologic failure, hep hepatologic failure, ECLS extracorporeal
life support, CNS central nervous system, GI gastrointestinal
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was a decrease of 1.6 VFD for each log increase in PAI-1
levels (Table 3).
Discussion
The important findings from this prospective study of 94
pediatric patients with ALI are that elevated plasma levels
of PAI-1 are associated with increased mortality and fewer
VFDs in pediatric patients with ALI, independent of age
and severity of illness. These results expand upon prior
findings in adults from an earlier study that examined the
relationship of plasma PAI-1 levels to clinical outcomes in
a cohort of 779 patients with ALI [9]. The study by Ware
and colleagues reported that among adults with ALI, the
odds of mortality increased by 2.0 for every log increase in
the level of PAI-1. In this study of children with ALI, we
found that the adjusted odds of mortality increased by 2.0
for every log increase in the level of plasma PAI-1 after
adjustment for age and severity of illness.
Early elevation of plasma PAI-1 could be a useful
biomarker of prognosis in pediatric patients with ALI
because the association of elevated plasma PAI-1 levels
with clinical outcomes was independent of age and
severity of illness at the time of presentation. Biomarkers
of prognosis can have value because they may help
identify patients who are at the greatest risk for poor
clinical outcomes, allowing therapeutic and preventive
interventions to be directed towards these more suscep-
tible patients. In addition, if causality can be established
in future studies, the biomarkers may provide targets for
pharmacologic intervention.
Intra-alveolar fibrin deposition, which is a pathologic
hallmark of ALI, may exert beneficial effects by sealing
leakage sites when the capillary endothelium and alveo-
lar epithelial barrier are compromised. However, severe
and persistent fibrin deposition can have deleterious
effects [10–14, 20–26]. Tissue-type and urokinase-type
plasminogen activators (uPA) activate plasminogen to
form plasmin, which degrades fibrin. PAI-1 is an endog-
enous inhibitor of the plasminogen activators and
therefore elevation of PAI-1 may lead to an unfavorable
balance of fibrin deposition and fibrinolysis [27, 28]. In
addition, uPA has a role in migration of inflammatory
cells [29]. PAI-1 also directly inhibits integrin-mediated
cell migration and thereby has a direct effect on the host
immune response as well [30, 31].
There are some limitations to this study. It was carried
out by combining subsets of patients from two prospec-
tive studies of ALI in whom plasma samples were
available. We combined patients from two studies
because there were not enough patients with plasma
samples collected in either of the studies individually.
Both studies prospectively identified patients with ALI
using the AECC criteria for definition of ALI. The dis-
tributions of predisposing conditions leading to ALI and
baseline demographics of the enrolled patients were
similar in the two studies (Table 1). There was a differ-
ence in the overall mortality in the two studies, which
probably is a reflection of historic trends of improving
mortality in ALI, most likely due to increasing use of
lung-protective ventilation strategies, and of the different
exclusion criteria in the two studies. The prone position-
ing study excluded patients with cardiovascular instability
[2]. We believe that patients with plasma samples inclu-
ded in the present study are a true representation of each
of the parent studies because the PaO2/FiO2, PRISM
scores, and VFDs among the subsets of patients for whom
plasma samples were available (and thus included in this
study) were not statistically different from the PaO2/FiO2,
PRISM scores, and VFDd for patients enrolled in each of
the parent studies.
In conclusion, the results from this study indicate that
early elevation of plasma PAI-1 is associated with higher
mortality and fewer VFDs among pediatric patients with
ALI, independent of age and severity of illness. These
findings support a likely role of altered fibrinolysis in the
pathogenesis of pediatric ALI and they also suggest that
elevated plasma PAI-1 may be a useful biomarker of
prognosis in patients with ALI. In addition, if causality
Table 3 Association of ventilator-free days and mortality and
PAI-1
Predictor
log PAI-1
levels
Linear regression
outcome: VFD
Logistic regression
outcome: mortality
Coefficient
[95% CI]
P Odds ratio
[95% CI]
P
Unadjusted -2.0 [-3.4 to 0.6] \0.01 1.75 [1.1–2.6] \0.01
Adjusteda -1.6 [-2.9 to 0.3] \0.02 2.0 [1.04–3.0] \0.02
a Adjusted for age and PRISM III
Fig. 2 Number of ventilator-free days (VFD) among patients
stratified by quartiles of plasma levels of plasma plasminogen
activator inhibitor-1 (PAI-1). The height of the bar represents the
median and the error bars represent the interquartile range (25th–
75th percentile) of the number of VFDs in each stratum of patients.
There was a decrease in the number of VFDs with increasing levels
of plasma PAI-1 (trend test P \ 0.02)
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can be established in future studies, PAI-1 may be a target
for future pharmacologic intervention.
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